Bulevirtide Acetate

CHEMBL5315080 Phase 4 Onaylandı Protein

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

— g/mol

LogP

—

Phase

4

An entry inhibitor used to treat chronic hepatitis delta virus infection in adults with compensated liver disease. It works by blocking the sodium taurocholate cotransporting polypeptide receptor that the hepatitis D virus uses to enter liver cells. It is the first approved therapy specifically targeting hepatitis delta.

Terapötik Alanlar

Hepatology

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

An entry inhibitor used to treat chronic hepatitis delta virus infection in adults with compensated liver disease. It works by blocking the sodium taurocholate cotransporting polypeptide receptor that the hepatitis D virus uses to enter liver cells. It is the first approved therapy specifically targeting hepatitis delta.

Yes, Bulevirtide Acetate is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL5315080. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

PillFYI

Hasta dostu bilgi mi arıyorsunuz?

Bulevirtide Acetate PillFYI'da

Hızlı Veriler

Dış Bağlantılar

ChEMBL CHEMBL5315080

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.